Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Implementation of RICA (ERAS) Guidelines in Grade II Acute Cholecystitis Undergoing Early Laparoscopic Cholecystectomy (COLERICA II)

6 luglio 2026 aggiornato da: Hospital d'Igualada

A Single-Centre, Non-Randomised Interventional Study for the Implementation of the Enhanced Recovery After Surgery (RICA) Guidelines in Patients With Tokyo Guidelines 2018 Grade II Acute Cholecystitis Undergoing Early Laparoscopic Cholecystectomy

Background Acute cholecystitis (sudden gallbladder inflammation, usually due to gallstones) is a highly frequent surgical emergency. For patients with moderate disease (Grade II, according to the international Tokyo Guidelines 2018), current standards recommend performing keyhole surgery (early laparoscopic cholecystectomy) within 72 hours of admission or up to 10 days from symptom onset. While the surgical timing is well-defined, care management before, during, and after surgery varies greatly. Standardised care pathways called RICA (Rehabilitación Multimodal en Cirugía del Adulto), which align with global Enhanced Recovery After Surgery (ERAS) protocols, use evidence-based steps to protect body function, reduce pain without heavy opioid use, and help patients walk and eat sooner. Although highly successful in planned surgeries, there is very little specific data or standard pathways regarding the application of these recovery protocols in urgent, complex cases like Grade II acute cholecystitis.

Purpose The main objective of this study is to evaluate the clinical efficiency and safety of implementing a standardized RICA perioperative care pathway in patients with Grade II acute cholecystitis undergoing early laparoscopic cholecystectomy, comparing them against a historical control group treated under conventional care.

Description

This single-centre, non-randomised interventional study uses a quasi-experimental, before-after design at the University Hospital of Igualada. The study will contrast two separate groups of adult patients aged between 18 and 85 years:

  • A historical control cohort (retrospective phase, 2023-2025) consisting of patients who received conventional, non-standardised care.
  • An intervention cohort (prospective phase, 2026-2029) consisting of patients treated strictly according to the new multidisciplinary RICA protocol.

The study aims to demonstrate that standardising care reduces the total postoperative length of hospital stay (measured in hours) without increasing surgical complications or unplanned readmissions. All clinical variables, including patient risks, surgical difficulty scales, complications up to 90 days, and protocol compliance rates, will be securely managed using an institutional REDCap database.

Panoramica dello studio

Descrizione dettagliata

Introduction and Clinical Framework

Acute cholecystitis constitutes one of the most prevalent acute surgical conditions managed within emergency departments across Europe. Epidemiological indicators highlight a rising incidence, particularly within the population over 65 years of age. While cholelithiasis affects approximately 10% to 15% of the general adult population, up to 40% of these individuals experience stone-related complications, with acute cholecystitis serving as the primary clinical manifestation in a substantial proportion of symptomatic cases.

The Tokyo Guidelines 2018 (TG18) represent the international gold standard for the diagnosis and severity stratification of this condition. Grade II (moderate) acute cholecystitis is characterised by marked local inflammation that complicates direct surgical management. Diagnostic features for Grade II include a marked leukocytosis (white blood cell count greater than 18,000/mm³), a tender palpable mass in the right upper abdominal quadrant, or a duration of clinical symptoms exceeding 72 hours. It also encompasses advanced local inflammatory findings confirmed via diagnostic imaging, such as gangrenous, emphysematous, or pericolecystic abscess formations, hepatic abscesses, or biliary peritonitis.

The seminal multi-centre randomised controlled trial (ACDC study) established the clinical superiority of early laparoscopic cholecystectomy over conservative management followed by delayed elective surgery, showing significant reductions in patient morbidity, hospital stay, and resource utilization. Current consensus guidelines from the World Society of Emergency Surgery (WSES) define early cholecystectomy as an intervention performed within 7 days of hospital admission or up to 10 days from the onset of clinical symptoms. While the technical advantages of early surgery in Grade II cases are recognised-offering a viable laparoscopic window before tissue fibrosis sets in-there is a critical lack of standardized perioperative management frameworks tailored specifically for this urgent, moderately severe cohort, as most general Enhanced Recovery After Surgery (ERAS) data originates from elective colorectal or mild (Grade I) cholecystitis pathways.

Study Objectives and Hypotheses

The primary objective of this study is to evaluate the clinical efficiency and recovery optimization of an institutional RICA protocol implementation for TG18 Grade II acute cholecystitis managed via early laparoscopic cholecystectomy. The core hypothesis is that the systematic and multi-professional standardisation of care will significantly reduce the postoperative length of hospital stay (measured precisely in hours) without increasing overall 90-day postoperative morbidity or unplanned hospital readmissions.

The secondary objectives are:

  1. To compare baseline characteristics and clinical outcomes between the intervention group and historical controls to assess protocol impact.
  2. To monitor perioperative morbidity by tracking the incidence and severity of surgical complications using the Clavien-Dindo classification up to 90 days postoperatively.
  3. To determine the rate and underlying causes of unplanned hospital readmissions within a 90-day postoperative window.

Methodology and Work Plan

This investigation employs a quasi-experimental, single-centre, before-after cohort design conducted at the University Hospital of Igualada (Catalonia, Spain). The study architecture is divided into two sequential chronological periods:

  • The Retrospective Phase (Historical Control Group, January 2023 - December 2025): Medical records of consecutive patients matching the inclusion criteria who underwent conventional surgical and perioperative care will be reviewed to establish a robust baseline.
  • The Prospective Phase (Intervention Group, March 2026 - February 2029): Consecutive patients will be prospectively enrolled, providing written informed consent, and managed strictly in accordance with the multidisciplinary RICA care matrix.

The project timeline dictates a one-week formal introduction to brief and align the departments of General Surgery, Anaesthesiology, and Emergency and Wards Nursing, alongside the deployment of the REDCap data infrastructure. The inclusion and data capture phase spans 36 months, followed by a 6-month data cleaning, 90-day follow-up completion, and final statistical analysis phase. The final 6 months are dedicated to scientific manuscript preparation following the TREND (Transparent Reporting of Evaluations with Nonrandomized Designs) statement guidelines.

The RICA Perioperative Care Matrix

The active intervention evaluated in this study replaces conventional practitioner-dependent management with a highly structured, time-sequenced multimodal care pathway involving surgeons, anaesthetists, and specialised nursing staff. The protocol is structured as follows:

  1. Preoperative Stage: Includes point-of-care ultrasound (POCUS) clinical assessment; systematic evaluation of surgical risk and patient frailty using validated clinical frailty scores; strict glycaemic control aiming to maintain blood glucose below 180 mg/dL; targeted antimicrobial prophylaxis governed by hospital antibiotic stewardship guidelines (PROA); active thermal management using forced-air warming blankets for vulnerable or frail individuals; and targeted patient education detailing early recovery objectives.
  2. Intraoperative Stage: Use of the surgical safety checklist; routine advanced monitoring; execution of standard or subtotal laparoscopic cholecystectomy (documenting fenestrated or reconstituted approaches, or conversion to open surgery); rapid sequence anaesthetic induction; controlled hyperoxia ($FiO_2$ 0.6 to 0.8); goal-directed fluid therapy (utilising non-invasive advanced haemodynamic monitoring systems like Clearsight) or weight-adjusted restrictive fluid administration (3-5 mL/kg/h); mandatory core normothermia maintenance; strict restriction of routine nasogastric tubes, urinary catheters, or abdominal drainage placement; and the mandatory application of opioid-sparing multimodal analgesia via local wound infiltration or Transversus Abdominis Plane (TAP) blocks.
  3. Immediate Postoperative Stage (Day 0): Continued active warming; oxygen therapy adjusted to blood oxygen saturation; multimodal non-opioid analgesia restricting morphic rescue doses; restrictive fluid maintenance; early mobilization protocol requiring sitting within 2 hours and active ambulation within 8 hours post-surgery; and early oral intake initiation (clear fluids) within 6 to 8 hours of the procedure.
  4. Postoperative Day 1: Progression to a liquid diet; active ambulation and targeted respiratory physiotherapy; transition to oral analgesia; discontinuation of intravenous fluid lines upon adequate oral tolerance; and initial evaluation for the removal of any intraoperatively placed drains or catheters.
  5. Postoperative Day 2 & Extended Stay: Advancement to a progressive low-fat biliary diet; full independent ambulation; continued oral analgesia and PROA-aligned antibiotic therapy; and daily formal assessment against discharge criteria.
  6. Discharge and Follow-up Criteria: Discharge is authorized only when the patient meets all standard criteria: absence of fever, adequate pain control via oral analgesia, complete independent ambulation, active patient acceptance, and a pre-discharge objective laboratory check measuring C-Reactive Protein (CRP) and liver function enzymes. Post-discharge care includes an institutional 24-hour telephone follow-up call, coordinated continuity with primary care medical teams, and a formal clinical follow-up assessment at 3 to 4 weeks.

Advanced Statistical Analysis Strategy

All data management will be executed utilizing the REDCap platform. Statistical computing will be performed using R software (version 4.3 or higher), with a fixed significance threshold of $p < 0.05$. Continuous variables will be evaluated for normality via the Shapiro-Wilk test and expressed as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical variables will be analysed using Chi-squared or Fisher's exact tests.

To evaluate the primary outcome (postoperative length of stay in hours), a multivariable linear regression model will be constructed. The dependent variable will be the log-transformed length of stay to account for non-normal distributions, with group allocation (RICA pathway vs. conventional care) serving as the main independent predictor. The model will be adjusted for key baseline covariates exhibiting unbalance, alongside established clinical confounders including age, ASA physical status, clinical frailty score, comorbidities, and initial biochemical severity indicators.

To account for the inherent selection bias of a non-randomised before-after design and mitigate period-related confounding, an advanced sensitivity analysis using Propensity Score Matching (PSM) will be implemented. Propensity scores will be calculated for each patient via a logistic regression model incorporating baseline demographics and clinical risks. Patients from the historical and prospective cohorts will be matched using a 1:1 nearest-neighbour algorithm, creating a balanced sub-cohort to isolate the true therapeutic effect of the RICA intervention.

Furthermore, a Cox proportional hazards regression model will be deployed to evaluate the time-to-discharge rate, treating the hospital discharge as the event of interest, complemented by Kaplan-Meier survival curves. To prove causal association, an institutional compliance index (0% to 100%) will be calculated for each intervention patient based on the percentage of RICA items fulfilled; a linear regression will test the direct correlation between high protocol adherence and reduced hospital stay. For the safety endpoint (Clavien-Dindo complications $\ge$ II), a formal non-inferiority analysis will be performed, applying a pre-specified safety margin of 5% to confirm that the RICA pathway does not compromise patient safety. Missing data patterns will be checked; if random and under 5%, complete-case analysis will be used, otherwise multiple imputation techniques will be applied.

Tipo di studio

Interventistico

Iscrizione (Stimato)

146

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Cesar Alejandro Anaya Romo, MD
  • Numero di telefono: +34680523403
  • Email: aanaya@csa.cat

Luoghi di studio

    • Barcelona
      • Igualada, Barcelona, Spagna, 08700
        • Hospital Universitari d'Igualada
        • Contatto:
          • Cristina Pozo Salgado, MSc
          • Numero di telefono: +34666441852
          • Email: cpozo@csa.cat
        • Contatto:
          • Marta Banque Navarro, PhD
          • Numero di telefono: +34938075585
          • Email: mbanque@csa.cat
        • Sub-investigatore:
          • Xavier Viñas Trullen, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Patients aged 18 to 85 years, inclusive.
  • Confirmed diagnosis of Grade II (moderate) acute cholecystitis based on the Tokyo Guidelines 2018 (TG18) criteria.
  • Patients scheduled for laparoscopic cholecystectomy within 72 hours of hospital admission and up to 10 days from symptom onset.
  • American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.

Exclusion Criteria:

  • Ongoing therapeutic anticoagulation or dual antiplatelet therapy that cannot be safely suspended or modified for surgery.
  • Concurrent advanced chronic liver disease (Child-Pugh class B or C), severe acute biliary pancreatitis, or associated complex biliary tract pathology.
  • Active SARS-CoV-2 (COVID-19) infection confirmed by polymerase chain reaction (PCR).
  • Refusal or inability to provide written informed consent for the prospective phase of the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Ricerca sui servizi sanitari
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: RICA Pathway
Prospective cohort of patients diagnosed with Tokyo Guidelines 2018 (TG18) Grade II acute cholecystitis managed prospectively between March 2026 and February 2029. Participants in this arm undergo early laparoscopic cholecystectomy within 72 hours of admission and are treated strictly according to the institutional multidisciplinary RICA (Rehabilitación Multimodal en Cirugía del Adulto) pathway. This evidence-based care bundle integrates pre-emptive frailty screening, restricted fasting windows, targeted point-of-care ultrasound (POCUS), strict perioperative glycaemic control (< 180 mg/dL), intraoperative goal-directed fluid therapy, mandatory maintenance of core normothermia, systematic avoidance of routine abdominal drains, and opioid-sparing multimodal analgesia (including abdominal wall blocks). Postoperative care dictates early mobilisation within 8 hours and early oral intake within 6 to 8 hours of surgery.
A standardized, multidisciplinary, evidence-based clinical pathway designed to optimize perioperative recovery for patients undergoing emergency laparoscopic cholecystectomy for Grade II acute cholecystitis. The intervention replaces conventional practitioner-dependent care with a highly structured time-matrix protocol including: preoperative point-of-care ultrasound (POCUS), frailty screening, restricted fasting windows, strict glycaemic control (<180 mg/dL), and antimicrobial stewardship; intraoperative goal-directed fluid therapy, mandatory core normothermia maintenance, restricted use of routine abdominal drains/catheters, and opioid-sparing multimodal analgesia (abdominal wall blocks); and postoperative early mobilization (within 8 hours), early oral intake (within 6 to 8 hours), and standardized multi-professional discharge criteria checking.
Nessun intervento: Conventional Care
Retrospective historical control cohort comprising patients diagnosed with Tokyo Guidelines 2018 (TG18) Grade II acute cholecystitis who underwent early laparoscopic cholecystectomy at the same institution between January 2023 and December 2025. Participants in this arm were managed under conventional, non-standardised perioperative care practices prior to the formal clinical implementation of the RICA pathway. Clinical decisions regarding preoperative fasting duration, intraoperative fluid management, routine placement of abdominal drains, nasogastric tubes, or urinary catheters, types of intraoperative analgesia (including reliance on systemic opioids), and milestones for postoperative mobilization and oral intake progression were dependent on individual practitioner preference and standard ward routines.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Length of Hospital Stay
Lasso di tempo: From the time of surgery completion up to formal hospital discharge (estimated up to 90 days postoperatively).
The total duration of hospitalisation calculated in hours, measured from the exact time of the completion of the laparoscopic cholecystectomy (skin closure) until the exact time of formal hospital discharge.
From the time of surgery completion up to formal hospital discharge (estimated up to 90 days postoperatively).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Morbidity Rate
Lasso di tempo: Up to 90 days postoperatively.
Incidence and severity of complications occurring after surgery, graded according to the international Clavien-Dindo classification. The primary safety focus will be on significant complications classified as Grade II or higher (Clavien-Dindo $\ge$ II), which include infections requiring specific antimicrobial therapies, leaks, or collections requiring intervention.
Up to 90 days postoperatively.
Unplanned Hospital Readmission Rate
Lasso di tempo: Up to 90 days post-discharge.
The percentage of patients requiring any unplanned or emergency hospital readmission related to the primary surgical condition, surgical site complications (such as intra-abdominal collections, surgical site infections, or biliary leaks), or systemic medical complications secondary to the intervention.
Up to 90 days post-discharge.
RICA Protocol Adherence Index
Lasso di tempo: From hospital admission up to formal hospital discharge (estimated up to 7 days).
An institutional compliance score calculated as the percentage of implemented RICA protocol care items successfully fulfilled for each patient out of the total applicable items across the preoperative, intraoperative, and postoperative care matrix (expressed as a continuous scale from 0% to 100%).
From hospital admission up to formal hospital discharge (estimated up to 7 days).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Cesar Alejandro Anaya Romo, MD, Consorci Sanitari de l'Anoia

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

10 luglio 2026

Completamento primario (Stimato)

28 febbraio 2029

Completamento dello studio (Stimato)

1 aprile 2029

Date di iscrizione allo studio

Primo inviato

6 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 luglio 2026

Primo Inserito (Effettivo)

10 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) will not be publicly shared due to explicit legal restrictions stipulated in the patient informed consent form approved by the institutional ethics committee. The approved protocol restricts data access strictly to the primary research team and its authorized internal collaborators to ensure compliance with the General Data Protection Regulation (GDPR) and national data protection laws. However, aggregate data and specific methodological details will be fully available in the final publication.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi